Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Unknown 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3

Conditions

Carcinoma, Non-Small-Cell Lung 20Nasopharyngeal Carcinoma 8Lung Neoplasms 7Colorectal Neoplasms 4Melanoma 3Esophageal Squamous Cell Carcinoma 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Sarcoma 2Osteosarcoma 2Nasopharyngeal Neoplasms 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Esophageal Neoplasms 2Unresectable Non-small Cell Lung Cancer 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Radiation Injuries 1Quality of Life 1Pleural Effusion, Malignant 1Non-squamous Non-small Cell Lung Cancer 1Neuroblastoma 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Esophageal 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Bone Neoplasms 1Advanced Pancreatic Cancer 1

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236Cyclophosphamide 135aldesleukin 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 68dabrafenib 65fludarabine phosphate 62sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35Magnetic Resonance Spectroscopy 33cobimetinib 32Specimen Handling 31Introns 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Melanoma × endostar protein × Clear all
NCT06965231 2025-05-11

FUMS-EDJS2024

Fudan University

Phase 2 Recruiting
58 enrolled
Dermatologic

Melanoma

NCT05907512 2023-06-22

Endostar Plus Toripalimab as Adjuvant Therapy for Resectable Stage III-Oligometastatic Stage IV Cutaneous Melanoma

Fudan University

Phase 2 Unknown
43 enrolled
Dermatologic

Melanoma

NCT03095079 2017-03-29

Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma

Peking University Cancer Hospital & Institute

Phase 2 Unknown
70 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡